Drugs / HS-20090-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04940845 | Jul 2021 → Jun 2022 | postmenopausal osteoporosis | Shanghai Hansoh Biomedical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20090-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04940845 ↗ |
| Route | Subcutaneous | “Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day” NCT04940845 ↗ |